Aura Biosciences (AURA) vs Pharming Group N.V. (PHAR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Aura Biosciences (AURA) has outperformed Pharming Group N.V. (PHAR) over the past year, gaining 12.2% versus a loss of 34.2%. Pharming Group N.V. is the larger company by market cap ($683.0 million vs $669.9 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AURA | PHAR |
|---|---|---|
| Share price | $6.46 | $9.65 |
| Market cap | $669.93M | $683.01M |
| 1-day change | +4.70% | -0.31% |
| YTD return | +18.53% | -45.39% |
| 1-year return | +12.15% | -34.22% |
| 5-year return | — | +2.22% |
| P/E ratio (TTM) | — | 74.23 |
| Forward P/E | — | 31.43 |
| EPS (TTM) | $-1.75 | $0.13 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $9.54 | $21.34 |
| 52-week low | $4.73 | $9.59 |
| Distance from 52-week high | -32.25% | -54.78% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +156.97% | +255.96% |
| Average volume | 748.04K | 23.12K |
| Shares outstanding | 103.70M | 70.78M |
| Employees | 113 | 407 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- AURA has outperformed PHAR by 46.4 percentage points over the past year.
About Aura Biosciences
AURA stock →Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision therapies to treat solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.
Healthcare · Biotechnology · 113 employees
About Pharming Group N.V.
PHAR stock →Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company's lead product is RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.
Healthcare · Biotechnology · 407 employees
AURA vs PHAR FAQ
Which is bigger, Aura Biosciences or Pharming Group N.V.?
Pharming Group N.V. (PHAR) is larger, with a market capitalization of $683.01M compared with $669.93M for Aura Biosciences (AURA).
Which stock has performed better over the past year, AURA or PHAR?
AURA returned +12.15% over the past 12 months, compared with -34.22% for PHAR (price return, excluding dividends). Past performance does not predict future results.
Are Aura Biosciences and Pharming Group N.V. in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.